Drug‐Induced Liver Injury Associated With Moxifloxacin: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System and a Real‐World Retrospective Study

Despite widespread clinical use, moxifloxacin's safety profile requires systematic evaluation. Clinicians should monitor liver function and integrate risk stratification, including albumin levels, gender and concomitant medications into prescribing practices. Elucidating DILI mechanisms and high-risk populations may optimize therapeutic decision-making and patient safety.